The rare disease small-batch CDMO market is expanding as biotech and pharma firms seek partners with expertise in rare disease manufacturing. This trend ensures efficiency and innovation in small-batch production. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Rare Disease Small-Batch CDMO Market, by Service Type
7.1.1. Process development & optimization
7.1.1.1. Market Revenue and Forecast
7.1.2. Analytical development & QC (stability, method validation)
7.1.2.1. Market Revenue and Forecast
7.1.3. Clinical-scale API / drug substance manufacturing (GMP)
7.1.3.1. Market Revenue and Forecast
7.1.4. Commercial-scale API manufacturing (GMP)
7.1.4.1. Market Revenue and Forecast
7.1.5. Formulation development & drug product (oral, sterile, transdermal)
7.1.5.1. Market Revenue and Forecast
7.1.6. Aseptic fill-finish / sterile terminal fill
7.1.6.1. Market Revenue and Forecast
7.1.7. Packaging & secondary packaging
7.1.7.1. Market Revenue and Forecast
7.1.8. Regulatory affairs & CMC consulting
7.1.8.1. Market Revenue and Forecast
7.1.9. Supply chain & cold-chain logistics
7.1.9.1. Market Revenue and Forecast
8.1. Rare Disease Small-Batch CDMO Market, by Modality/Technology
8.1.1. Small molecules (API + finished dosage)
8.1.1.1. Market Revenue and Forecast
8.1.2. Biologics (mAbs, proteins)
8.1.2.1. Market Revenue and Forecast
8.1.3. Cell Therapies (Autologous/Allogeneic)
8.1.3.1. Market Revenue and Forecast
8.1.4. Viral-Vector Gene Therapies (AAV, Lentiviral)
8.1.4.1. Market Revenue and Forecast
8.1.5. Oligonucleotides & ASOs/siRNA
8.1.5.1. Market Revenue and Forecast
8.1.6. mRNA therapeutics & vaccines
8.1.6.1. Market Revenue and Forecast
8.1.7. Conjugates (ADC, Radioconjugates)
8.1.7.1. Market Revenue and Forecast
9.1. Rare Disease Small-Batch CDMO Market, by Batch/Scale Type
9.1.1. Micro/Bench Scale (Preclinical)
9.1.1.1. Market Revenue and Forecast
9.1.2. Clinical Small-Batch (Phase I/II) — Single-Lot Supply For Trials/Compassionate Use
9.1.2.1. Market Revenue and Forecast
9.1.3. Commercial Small-Batch (Or Niche Commercial)
9.1.3.1. Market Revenue and Forecast
9.1.4. Campaign Manufacturing (Multiple Small Runs)
9.1.4.1. Market Revenue and Forecast
10.1. Rare Disease Small-Batch CDMO Market, by Development Stage
10.1.1. Discovery / Preclinical Support
10.1.1.1. Market Revenue and Forecast
10.1.2. IND/CTA Enabling (toxicology, GMP batches)
10.1.2.1. Market Revenue and Forecast
10.1.3. Clinical Supply (Phases I–III)
10.1.3.1. Market Revenue and Forecast
10.1.4. Tech Transfer & Scale-Up To Commercialization
10.1.4.1. Market Revenue and Forecast
10.1.5. Post-Approval/ Commercial Supply (Limited Volumes)
10.1.5.1. Market Revenue and Forecast
11.1. Rare Disease Small-Batch CDMO Market, by Therapeutic Area/Indication
11.1.1. Genetic/Neurodegenerative Rare Diseases
11.1.1.1. Market Revenue and Forecast
11.1.2. Rare Oncology / Hematologic Disorders
11.1.2.1. Market Revenue and Forecast
11.1.3. Metabolic & Enzyme-Replacement Indications
11.1.3.1. Market Revenue and Forecast
11.1.4. Ophthalmology, Rare Cardiomyopathies, And Rare Pulmonary Diseases
11.1.4.1. Market Revenue and Forecast
12.1. Rare Disease Small-Batch CDMO Market, by Customer Type
12.1.1. Small Biotech / Orphan-Drug Startups
12.1.1.1. Market Revenue and Forecast
12.1.2. Virtual Biotechs / Academic Spinouts
12.1.2.1. Market Revenue and Forecast
12.1.3. Mid-Sized Pharma/Specialty Pharma
12.1.3.1. Market Revenue and Forecast
12.1.4. Large Pharma (Outsourcing Niche Programs)
12.1.4.1. Market Revenue and Forecast
13.1. Rare Disease Small-Batch CDMO Market, by Contract Model
13.1.1. Fee-For-Service (Time & Materials)
13.1.1.1. Market Revenue and Forecast
13.1.2. Fixed-Price Project / Milestone-Based
13.1.2.1. Market Revenue and Forecast
13.1.3. Risk/Reward (Revenue-Share, Royalty)
13.1.3.1. Market Revenue and Forecast
13.1.4. Long-Term Strategic Supply Agreements/Capacity Reservation
13.1.4.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Service Type
14.1.2. Market Revenue and Forecast, by Modality/Technology
14.1.3. Market Revenue and Forecast, by Batch/Scale Type
14.1.4. Market Revenue and Forecast, by Development Stage
14.1.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.1.6. Market Revenue and Forecast, by Contract Model
14.1.7. Market Revenue and Forecast, by Customer Type
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Service Type
14.1.8.2. Market Revenue and Forecast, by Modality/Technology
14.1.8.3. Market Revenue and Forecast, by Batch/Scale Type
14.1.8.4. Market Revenue and Forecast, by Development Stage
14.1.8.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.1.8.6. Market Revenue and Forecast, by Contract Model
14.1.8.7. Market Revenue and Forecast, by Customer Type
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Service Type
14.1.9.2. Market Revenue and Forecast, by Modality/Technology
14.1.9.3. Market Revenue and Forecast, by Batch/Scale Type
14.1.9.4. Market Revenue and Forecast, by Development Stage
14.1.9.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.1.9.6. Market Revenue and Forecast, by Contract Model
14.1.9.7. Market Revenue and Forecast, by Customer Type
14.2. Europe
14.2.1. Market Revenue and Forecast, by Service Type
14.2.2. Market Revenue and Forecast, by Modality/Technology
14.2.3. Market Revenue and Forecast, by Batch/Scale Type
14.2.4. Market Revenue and Forecast, by Development Stage
14.2.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.2.6. Market Revenue and Forecast, by Contract Model
14.2.7. Market Revenue and Forecast, by Customer Type
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Service Type
14.2.8.2. Market Revenue and Forecast, by Modality/Technology
14.2.8.3. Market Revenue and Forecast, by Batch/Scale Type
14.2.8.4. Market Revenue and Forecast, by Development Stage
14.2.8.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.2.8.6. Market Revenue and Forecast, by Contract Model
14.2.8.7. Market Revenue and Forecast, by Customer Type
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Service Type
14.2.9.2. Market Revenue and Forecast, by Modality/Technology
14.2.9.3. Market Revenue and Forecast, by Batch/Scale Type
14.2.9.4. Market Revenue and Forecast, by Development Stage
14.2.9.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.2.9.6. Market Revenue and Forecast, by Contract Model
14.2.9.7. Market Revenue and Forecast, by Customer Type
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Service Type
14.2.10.2. Market Revenue and Forecast, by Modality/Technology
14.2.10.3. Market Revenue and Forecast, by Batch/Scale Type
14.2.10.4. Market Revenue and Forecast, by Development Stage
14.2.10.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.2.10.6. Market Revenue and Forecast, by Contract Model
14.2.10.7. Market Revenue and Forecast, by Customer Type
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Service Type
14.2.11.2. Market Revenue and Forecast, by Modality/Technology
14.2.11.3. Market Revenue and Forecast, by Batch/Scale Type
14.2.11.4. Market Revenue and Forecast, by Development Stage
14.2.11.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.2.11.6. Market Revenue and Forecast, by Contract Model
14.2.11.7. Market Revenue and Forecast, by Customer Type
14.3. APAC
14.3.1. Market Revenue and Forecast, by Service Type
14.3.2. Market Revenue and Forecast, by Modality/Technology
14.3.3. Market Revenue and Forecast, by Batch/Scale Type
14.3.4. Market Revenue and Forecast, by Development Stage
14.3.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.3.6. Market Revenue and Forecast, by Contract Model
14.3.7. Market Revenue and Forecast, by Customer Type
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Service Type
14.3.8.2. Market Revenue and Forecast, by Modality/Technology
14.3.8.3. Market Revenue and Forecast, by Batch/Scale Type
14.3.8.4. Market Revenue and Forecast, by Development Stage
14.3.8.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.3.8.6. Market Revenue and Forecast, by Contract Model
14.3.8.7. Market Revenue and Forecast, by Customer Type
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Service Type
14.3.9.2. Market Revenue and Forecast, by Modality/Technology
14.3.9.3. Market Revenue and Forecast, by Batch/Scale Type
14.3.9.4. Market Revenue and Forecast, by Development Stage
14.3.9.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.3.9.6. Market Revenue and Forecast, by Contract Model
14.3.9.7. Market Revenue and Forecast, by Customer Type
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Service Type
14.3.10.2. Market Revenue and Forecast, by Modality/Technology
14.3.10.3. Market Revenue and Forecast, by Batch/Scale Type
14.3.10.4. Market Revenue and Forecast, by Development Stage
14.3.10.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.3.10.6. Market Revenue and Forecast, by Contract Model
14.3.10.7. Market Revenue and Forecast, by Customer Type
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Service Type
14.3.11.2. Market Revenue and Forecast, by Modality/Technology
14.3.11.3. Market Revenue and Forecast, by Batch/Scale Type
14.3.11.4. Market Revenue and Forecast, by Development Stage
14.3.11.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.3.11.6. Market Revenue and Forecast, by Contract Model
14.3.11.7. Market Revenue and Forecast, by Customer Type
14.4. MEA
14.4.1. Market Revenue and Forecast, by Service Type
14.4.2. Market Revenue and Forecast, by Modality/Technology
14.4.3. Market Revenue and Forecast, by Batch/Scale Type
14.4.4. Market Revenue and Forecast, by Development Stage
14.4.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.4.6. Market Revenue and Forecast, by Contract Model
14.4.7. Market Revenue and Forecast, by Customer Type
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Service Type
14.4.8.2. Market Revenue and Forecast, by Modality/Technology
14.4.8.3. Market Revenue and Forecast, by Batch/Scale Type
14.4.8.4. Market Revenue and Forecast, by Development Stage
14.4.8.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.4.8.6. Market Revenue and Forecast, by Contract Model
14.4.8.7. Market Revenue and Forecast, by Customer Type
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Service Type
14.4.9.2. Market Revenue and Forecast, by Modality/Technology
14.4.9.3. Market Revenue and Forecast, by Batch/Scale Type
14.4.9.4. Market Revenue and Forecast, by Development Stage
14.4.9.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.4.9.6. Market Revenue and Forecast, by Contract Model
14.4.9.7. Market Revenue and Forecast, by Customer Type
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Service Type
14.4.10.2. Market Revenue and Forecast, by Modality/Technology
14.4.10.3. Market Revenue and Forecast, by Batch/Scale Type
14.4.10.4. Market Revenue and Forecast, by Development Stage
14.4.10.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.4.10.6. Market Revenue and Forecast, by Contract Model
14.4.10.7. Market Revenue and Forecast, by Customer Type
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Service Type
14.4.11.2. Market Revenue and Forecast, by Modality/Technology
14.4.11.3. Market Revenue and Forecast, by Batch/Scale Type
14.4.11.4. Market Revenue and Forecast, by Development Stage
14.4.11.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.4.11.6. Market Revenue and Forecast, by Contract Model
14.4.11.7. Market Revenue and Forecast, by Customer Type
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Service Type
14.5.2. Market Revenue and Forecast, by Modality/Technology
14.5.3. Market Revenue and Forecast, by Batch/Scale Type
14.5.4. Market Revenue and Forecast, by Development Stage
14.5.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.5.6. Market Revenue and Forecast, by Contract Model
14.5.7. Market Revenue and Forecast, by Customer Type
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Service Type
14.5.8.2. Market Revenue and Forecast, by Modality/Technology
14.5.8.3. Market Revenue and Forecast, by Batch/Scale Type
14.5.8.4. Market Revenue and Forecast, by Development Stage
14.5.8.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.5.8.6. Market Revenue and Forecast, by Contract Model
14.5.8.7. Market Revenue and Forecast, by Customer Type
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Service Type
14.5.9.2. Market Revenue and Forecast, by Modality/Technology
14.5.9.3. Market Revenue and Forecast, by Batch/Scale Type
14.5.9.4. Market Revenue and Forecast, by Development Stage
14.5.9.5. Market Revenue and Forecast, by Therapeutic Area/Indication
14.5.9.6. Market Revenue and Forecast, by Contract Model
14.5.9.7. Market Revenue and Forecast, by Customer Type
15.1. Lonza.
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Catalent.
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Thermo Fisher Scientific / Patheon.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. WuXi Biologics / WuXi AppTec.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Samsung Biologics.
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. FUJIFILM Diosynth Biotechnologies.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Ajinomoto Bio-Pharma Services (ABP).
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. BioVectra (Agilent/BioVectra).
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Alcami.
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. CordenPharma.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description